CTXR Key Statistics, Chart & Performance
The current stock price of CTXR is 0.8565 USD. In the past month the price decreased by -22.14%. In the past year, price decreased by -74.05%.
CTXR Technical Analysis
CTXR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CTXR. Both the profitability and financial health of CTXR have multiple concerns.
CTXR Financial Highlights
Over the last trailing twelve months CTXR reported a non-GAAP Earnings per Share(EPS) of -5.84. The EPS increased by 36.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.59% | ||
| ROE | -55.42% | ||
| Debt/Equity | 0.01 |
CTXR Forecast & Estimates
8 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 495.45% is expected in the next year compared to the current price of 0.8565.
CTXR Ownership
CTXR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.97 | 976.55B | ||
| JNJ | JOHNSON & JOHNSON | 21.15 | 529.01B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.43B | ||
| PFE | PFIZER INC | 8.09 | 147.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.63 | 115.26B | ||
| ZTS | ZOETIS INC | 19.76 | 55.21B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 5.51 | 14.79B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.19 | 12.01B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.78B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.35B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.22B |
Related stock screener links
About CTXR
Company Profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Company Info
CITIUS PHARMACEUTICALS INC
11 Commerce Dr Fl 1
Cranford NEW JERSEY 07016 US
CEO: Myron Holubiak
Employees: 23
Phone: 19089676677
CITIUS PHARMACEUTICALS INC / CTXR FAQ
What does CTXR do?
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
What is the stock price of CITIUS PHARMACEUTICALS INC today?
The current stock price of CTXR is 0.8565 USD. The price decreased by -0.73% in the last trading session.
Does CITIUS PHARMACEUTICALS INC pay dividends?
CTXR does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTXR stock?
CTXR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is CTXR stock listed?
CTXR stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of CITIUS PHARMACEUTICALS INC (CTXR)?
CITIUS PHARMACEUTICALS INC (CTXR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.84).
Can you provide the market cap for CITIUS PHARMACEUTICALS INC?
CITIUS PHARMACEUTICALS INC (CTXR) has a market capitalization of 13.65M USD. This makes CTXR a Nano Cap stock.